JAC Advance Access published online on April 29, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh200
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 INSERM U593, Université Victor
Ségalen, 146 rue Léo Saignat, 33076 Bordeaux;
* To whom correspondence should be addressed. E-mail: Maria.Winnock{at}isped.u-bordeaux2.fr.
Since human immunodeficiency virus (HIV) and hepatitis
C virus (HCV) share the same modes of transmission, HIV-HCV
co-infected patients are relatively common. Until recently, the
clinical course of HCV in co-infected patients was overshadowed
by the high morbidity and mortality of HIV disease. Recent reductions
in morbidity and mortality among HIV-infected patients due to the
advent of highly active antiretroviral therapy (HAART), have contributed
to the emergence of HCV as a significant viral pathogen in this
population. This article reviews the current evidence on the epidemiology
and clinical implications of an interaction between HIV-1 and HCV
infections.
Review
Interaction between HIV-1 and HCV infections: towards
a new entity?
2 Department of Internal Medicine,
Hôpital Cochin, Paris, France
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. McNelis Management of Hepatitis C Infection in the HIV-Infected Patient Journal of Pharmacy Practice, February 1, 2006; 19(1): 37 - 52. [Abstract] [PDF] |
||||
